Nucleosides and Nucleotides. 141. Chemical Stability of a New Antitumor Nucleoside, 2'-C-Cyano-2'-deoxy-1-.beta.-D-arabino-pentofuranosylcytosine (CNDAC) in Alkaline Medium: Formation of 2'-C-Cyano-2'-deoxy-1-.beta.-D-ribo-pentofuranosylcytosine (CNDC) and Its Antitumor Activity

We have designed 2'-C-cyano-2'-deoxy-1-beta-D-arabino- pentofuranosylcytosine (CNDAC) as a potential mechanism-based DNA-strand-breaking nucleoside, which showed potent tumor cell growth inhibitory activity against various human tumor cell lines in vitro and in vivo. When measuring the pKa...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of medicinal chemistry 1995-08, Vol.38 (17), p.3391-3397
Hauptverfasser: Azuma, Atsushi, Hanaoka, Kenji, Kurihara, Atsushi, Kobayashi, Tomowo, Miyauchi, Seiji, Kamo, Naoki, Tanaka, Motohiro, Sasaki, Takuma, Matsuda, Akira
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 3397
container_issue 17
container_start_page 3391
container_title Journal of medicinal chemistry
container_volume 38
creator Azuma, Atsushi
Hanaoka, Kenji
Kurihara, Atsushi
Kobayashi, Tomowo
Miyauchi, Seiji
Kamo, Naoki
Tanaka, Motohiro
Sasaki, Takuma
Matsuda, Akira
description We have designed 2'-C-cyano-2'-deoxy-1-beta-D-arabino- pentofuranosylcytosine (CNDAC) as a potential mechanism-based DNA-strand-breaking nucleoside, which showed potent tumor cell growth inhibitory activity against various human tumor cell lines in vitro and in vivo. When measuring the pKa of the 2' alpha-proton of CNDAC, we found that CNDAC epimerized to 2'-C-cyano-2'-deoxy-1-beta-D-ribo-pentofuranosylcytosine (CNDC) with concomitant degradation of both CNDAC and CNDC to cytosine and 1,4-anhydro-2-C-cyano-2-deoxy-D-erythro-pent-1- enitol. Kinetic analysis of these reactions showed that abstraction of the acidic 2'-proton of CNDAC and CNDC initiated the reactions, which quickly reached an equilibrium. In the equilibrium, a concentration ratio of CNDAC and CNDC was about 3:5. Concomitant degradation of these nucleosides was found to be rather slow. Deuterium incorporation experiments with CNDAC in a D2O buffer suggested the mechanism of the beta-elimination reactions is an E1cB type. These epimerization and degradation reactions were found even in neutral conditions (pH 7.5) and also occurred in RPMI 1640 cell culture medium. The discovery of which nucleoside possesses the predominate tumor cell growth inhibitory activity was important. While both nucleosides showed potent tumor cell growth inhibitory activity against three human tumor cell lines (colon carcinoma WiDr, small cell lung carcinoma SBC-5, and stomach carcinoma MKN-74 cells) in 48 h of incubation, in 20 min of incubation, CNDAC was 11-50 times more effective than CNDC. In vivo antileukemic activity of these nucleosides against a mouse P388 model, CNDAC was obviously superior to CNDC.
doi_str_mv 10.1021/jm00017a023
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_77463046</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>16961104</sourcerecordid><originalsourceid>FETCH-LOGICAL-a451t-87a7c4cac544fd5a5475d11fb46857598fd20282ecae842e01eeffabd940a3053</originalsourceid><addsrcrecordid>eNqFks1v0zAYxgMCjTI4ceCE5BMDgYvt2HHKrcpYmTQK0gbiZr1xHOEuiYvtwPLf46rT2AGxg-WP5-fn8Wu9WfaMkjkljL7b9IQQKoGw_H42o4IRzEvCH2QzQhjDrGD5o-xxCJuE5ZTlB9mBLAQpFmx27_l61J1xwTYmIBgatN_H3X6OKKdzVP0wvdXQofMIte1snJBrEaC1-Y2WQ7Rx7J1Hf33eInaEK1xNMDiclo1xVxOmeF6bCHN8jMEnn6RtzRBdO_rEhanTU0zXB4NeVevjZfUa2QEtu0vodmefTGPH_j06cb6HaN2we8IdMd7W_81IEbuCT2O4VcZSR_srlfgke9hCF8zT6_kw-3ry4aL6iM8-r06r5RkGLmjEpQSpuQYtOG8bAYJL0VDa1rwohRSLsm0YYSUzGkzJmSHUmLaFullwAjkR-WH2cu-79e7naEJUvQ3adB0Mxo1BScmLnKRxF0iLRUEp4Ql8swe1dyF406qttz34SVGidv2ibvVLol9c2451b5ob9rpBko73ug3RXN3I4C9VIXMp1MWXcyW_rUq5yqX6nvijPQ86qI0b_ZB-75_JfwDQCtXl</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>16961104</pqid></control><display><type>article</type><title>Nucleosides and Nucleotides. 141. Chemical Stability of a New Antitumor Nucleoside, 2'-C-Cyano-2'-deoxy-1-.beta.-D-arabino-pentofuranosylcytosine (CNDAC) in Alkaline Medium: Formation of 2'-C-Cyano-2'-deoxy-1-.beta.-D-ribo-pentofuranosylcytosine (CNDC) and Its Antitumor Activity</title><source>MEDLINE</source><source>ACS Publications</source><creator>Azuma, Atsushi ; Hanaoka, Kenji ; Kurihara, Atsushi ; Kobayashi, Tomowo ; Miyauchi, Seiji ; Kamo, Naoki ; Tanaka, Motohiro ; Sasaki, Takuma ; Matsuda, Akira</creator><creatorcontrib>Azuma, Atsushi ; Hanaoka, Kenji ; Kurihara, Atsushi ; Kobayashi, Tomowo ; Miyauchi, Seiji ; Kamo, Naoki ; Tanaka, Motohiro ; Sasaki, Takuma ; Matsuda, Akira</creatorcontrib><description>We have designed 2'-C-cyano-2'-deoxy-1-beta-D-arabino- pentofuranosylcytosine (CNDAC) as a potential mechanism-based DNA-strand-breaking nucleoside, which showed potent tumor cell growth inhibitory activity against various human tumor cell lines in vitro and in vivo. When measuring the pKa of the 2' alpha-proton of CNDAC, we found that CNDAC epimerized to 2'-C-cyano-2'-deoxy-1-beta-D-ribo-pentofuranosylcytosine (CNDC) with concomitant degradation of both CNDAC and CNDC to cytosine and 1,4-anhydro-2-C-cyano-2-deoxy-D-erythro-pent-1- enitol. Kinetic analysis of these reactions showed that abstraction of the acidic 2'-proton of CNDAC and CNDC initiated the reactions, which quickly reached an equilibrium. In the equilibrium, a concentration ratio of CNDAC and CNDC was about 3:5. Concomitant degradation of these nucleosides was found to be rather slow. Deuterium incorporation experiments with CNDAC in a D2O buffer suggested the mechanism of the beta-elimination reactions is an E1cB type. These epimerization and degradation reactions were found even in neutral conditions (pH 7.5) and also occurred in RPMI 1640 cell culture medium. The discovery of which nucleoside possesses the predominate tumor cell growth inhibitory activity was important. While both nucleosides showed potent tumor cell growth inhibitory activity against three human tumor cell lines (colon carcinoma WiDr, small cell lung carcinoma SBC-5, and stomach carcinoma MKN-74 cells) in 48 h of incubation, in 20 min of incubation, CNDAC was 11-50 times more effective than CNDC. In vivo antileukemic activity of these nucleosides against a mouse P388 model, CNDAC was obviously superior to CNDC.</description><identifier>ISSN: 0022-2623</identifier><identifier>EISSN: 1520-4804</identifier><identifier>DOI: 10.1021/jm00017a023</identifier><identifier>PMID: 7650692</identifier><language>eng</language><publisher>United States: American Chemical Society</publisher><subject>Adenocarcinoma - pathology ; Animals ; Antineoplastic Agents - chemical synthesis ; Antineoplastic Agents - pharmacology ; Cell Division - drug effects ; Colonic Neoplasms - pathology ; Cytarabine - analogs &amp; derivatives ; Cytarabine - chemical synthesis ; Cytarabine - chemistry ; Cytarabine - pharmacology ; Drug Stability ; Female ; Humans ; Hydrogen-Ion Concentration ; Leukemia P388 - pathology ; Mice ; Mice, Inbred DBA ; Ribonucleosides - chemical synthesis ; Ribonucleosides - chemistry ; Ribonucleosides - pharmacology ; Spectrum Analysis ; Tumor Cells, Cultured</subject><ispartof>Journal of medicinal chemistry, 1995-08, Vol.38 (17), p.3391-3397</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a451t-87a7c4cac544fd5a5475d11fb46857598fd20282ecae842e01eeffabd940a3053</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://pubs.acs.org/doi/pdf/10.1021/jm00017a023$$EPDF$$P50$$Gacs$$H</linktopdf><linktohtml>$$Uhttps://pubs.acs.org/doi/10.1021/jm00017a023$$EHTML$$P50$$Gacs$$H</linktohtml><link.rule.ids>314,780,784,2765,27076,27924,27925,56738,56788</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7650692$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Azuma, Atsushi</creatorcontrib><creatorcontrib>Hanaoka, Kenji</creatorcontrib><creatorcontrib>Kurihara, Atsushi</creatorcontrib><creatorcontrib>Kobayashi, Tomowo</creatorcontrib><creatorcontrib>Miyauchi, Seiji</creatorcontrib><creatorcontrib>Kamo, Naoki</creatorcontrib><creatorcontrib>Tanaka, Motohiro</creatorcontrib><creatorcontrib>Sasaki, Takuma</creatorcontrib><creatorcontrib>Matsuda, Akira</creatorcontrib><title>Nucleosides and Nucleotides. 141. Chemical Stability of a New Antitumor Nucleoside, 2'-C-Cyano-2'-deoxy-1-.beta.-D-arabino-pentofuranosylcytosine (CNDAC) in Alkaline Medium: Formation of 2'-C-Cyano-2'-deoxy-1-.beta.-D-ribo-pentofuranosylcytosine (CNDC) and Its Antitumor Activity</title><title>Journal of medicinal chemistry</title><addtitle>J. Med. Chem</addtitle><description>We have designed 2'-C-cyano-2'-deoxy-1-beta-D-arabino- pentofuranosylcytosine (CNDAC) as a potential mechanism-based DNA-strand-breaking nucleoside, which showed potent tumor cell growth inhibitory activity against various human tumor cell lines in vitro and in vivo. When measuring the pKa of the 2' alpha-proton of CNDAC, we found that CNDAC epimerized to 2'-C-cyano-2'-deoxy-1-beta-D-ribo-pentofuranosylcytosine (CNDC) with concomitant degradation of both CNDAC and CNDC to cytosine and 1,4-anhydro-2-C-cyano-2-deoxy-D-erythro-pent-1- enitol. Kinetic analysis of these reactions showed that abstraction of the acidic 2'-proton of CNDAC and CNDC initiated the reactions, which quickly reached an equilibrium. In the equilibrium, a concentration ratio of CNDAC and CNDC was about 3:5. Concomitant degradation of these nucleosides was found to be rather slow. Deuterium incorporation experiments with CNDAC in a D2O buffer suggested the mechanism of the beta-elimination reactions is an E1cB type. These epimerization and degradation reactions were found even in neutral conditions (pH 7.5) and also occurred in RPMI 1640 cell culture medium. The discovery of which nucleoside possesses the predominate tumor cell growth inhibitory activity was important. While both nucleosides showed potent tumor cell growth inhibitory activity against three human tumor cell lines (colon carcinoma WiDr, small cell lung carcinoma SBC-5, and stomach carcinoma MKN-74 cells) in 48 h of incubation, in 20 min of incubation, CNDAC was 11-50 times more effective than CNDC. In vivo antileukemic activity of these nucleosides against a mouse P388 model, CNDAC was obviously superior to CNDC.</description><subject>Adenocarcinoma - pathology</subject><subject>Animals</subject><subject>Antineoplastic Agents - chemical synthesis</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Cell Division - drug effects</subject><subject>Colonic Neoplasms - pathology</subject><subject>Cytarabine - analogs &amp; derivatives</subject><subject>Cytarabine - chemical synthesis</subject><subject>Cytarabine - chemistry</subject><subject>Cytarabine - pharmacology</subject><subject>Drug Stability</subject><subject>Female</subject><subject>Humans</subject><subject>Hydrogen-Ion Concentration</subject><subject>Leukemia P388 - pathology</subject><subject>Mice</subject><subject>Mice, Inbred DBA</subject><subject>Ribonucleosides - chemical synthesis</subject><subject>Ribonucleosides - chemistry</subject><subject>Ribonucleosides - pharmacology</subject><subject>Spectrum Analysis</subject><subject>Tumor Cells, Cultured</subject><issn>0022-2623</issn><issn>1520-4804</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1995</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFks1v0zAYxgMCjTI4ceCE5BMDgYvt2HHKrcpYmTQK0gbiZr1xHOEuiYvtwPLf46rT2AGxg-WP5-fn8Wu9WfaMkjkljL7b9IQQKoGw_H42o4IRzEvCH2QzQhjDrGD5o-xxCJuE5ZTlB9mBLAQpFmx27_l61J1xwTYmIBgatN_H3X6OKKdzVP0wvdXQofMIte1snJBrEaC1-Y2WQ7Rx7J1Hf33eInaEK1xNMDiclo1xVxOmeF6bCHN8jMEnn6RtzRBdO_rEhanTU0zXB4NeVevjZfUa2QEtu0vodmefTGPH_j06cb6HaN2we8IdMd7W_81IEbuCT2O4VcZSR_srlfgke9hCF8zT6_kw-3ry4aL6iM8-r06r5RkGLmjEpQSpuQYtOG8bAYJL0VDa1rwohRSLsm0YYSUzGkzJmSHUmLaFullwAjkR-WH2cu-79e7naEJUvQ3adB0Mxo1BScmLnKRxF0iLRUEp4Ql8swe1dyF406qttz34SVGidv2ibvVLol9c2451b5ob9rpBko73ug3RXN3I4C9VIXMp1MWXcyW_rUq5yqX6nvijPQ86qI0b_ZB-75_JfwDQCtXl</recordid><startdate>19950801</startdate><enddate>19950801</enddate><creator>Azuma, Atsushi</creator><creator>Hanaoka, Kenji</creator><creator>Kurihara, Atsushi</creator><creator>Kobayashi, Tomowo</creator><creator>Miyauchi, Seiji</creator><creator>Kamo, Naoki</creator><creator>Tanaka, Motohiro</creator><creator>Sasaki, Takuma</creator><creator>Matsuda, Akira</creator><general>American Chemical Society</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TM</scope><scope>7X8</scope></search><sort><creationdate>19950801</creationdate><title>Nucleosides and Nucleotides. 141. Chemical Stability of a New Antitumor Nucleoside, 2'-C-Cyano-2'-deoxy-1-.beta.-D-arabino-pentofuranosylcytosine (CNDAC) in Alkaline Medium: Formation of 2'-C-Cyano-2'-deoxy-1-.beta.-D-ribo-pentofuranosylcytosine (CNDC) and Its Antitumor Activity</title><author>Azuma, Atsushi ; Hanaoka, Kenji ; Kurihara, Atsushi ; Kobayashi, Tomowo ; Miyauchi, Seiji ; Kamo, Naoki ; Tanaka, Motohiro ; Sasaki, Takuma ; Matsuda, Akira</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a451t-87a7c4cac544fd5a5475d11fb46857598fd20282ecae842e01eeffabd940a3053</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1995</creationdate><topic>Adenocarcinoma - pathology</topic><topic>Animals</topic><topic>Antineoplastic Agents - chemical synthesis</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Cell Division - drug effects</topic><topic>Colonic Neoplasms - pathology</topic><topic>Cytarabine - analogs &amp; derivatives</topic><topic>Cytarabine - chemical synthesis</topic><topic>Cytarabine - chemistry</topic><topic>Cytarabine - pharmacology</topic><topic>Drug Stability</topic><topic>Female</topic><topic>Humans</topic><topic>Hydrogen-Ion Concentration</topic><topic>Leukemia P388 - pathology</topic><topic>Mice</topic><topic>Mice, Inbred DBA</topic><topic>Ribonucleosides - chemical synthesis</topic><topic>Ribonucleosides - chemistry</topic><topic>Ribonucleosides - pharmacology</topic><topic>Spectrum Analysis</topic><topic>Tumor Cells, Cultured</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Azuma, Atsushi</creatorcontrib><creatorcontrib>Hanaoka, Kenji</creatorcontrib><creatorcontrib>Kurihara, Atsushi</creatorcontrib><creatorcontrib>Kobayashi, Tomowo</creatorcontrib><creatorcontrib>Miyauchi, Seiji</creatorcontrib><creatorcontrib>Kamo, Naoki</creatorcontrib><creatorcontrib>Tanaka, Motohiro</creatorcontrib><creatorcontrib>Sasaki, Takuma</creatorcontrib><creatorcontrib>Matsuda, Akira</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Nucleic Acids Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Azuma, Atsushi</au><au>Hanaoka, Kenji</au><au>Kurihara, Atsushi</au><au>Kobayashi, Tomowo</au><au>Miyauchi, Seiji</au><au>Kamo, Naoki</au><au>Tanaka, Motohiro</au><au>Sasaki, Takuma</au><au>Matsuda, Akira</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Nucleosides and Nucleotides. 141. Chemical Stability of a New Antitumor Nucleoside, 2'-C-Cyano-2'-deoxy-1-.beta.-D-arabino-pentofuranosylcytosine (CNDAC) in Alkaline Medium: Formation of 2'-C-Cyano-2'-deoxy-1-.beta.-D-ribo-pentofuranosylcytosine (CNDC) and Its Antitumor Activity</atitle><jtitle>Journal of medicinal chemistry</jtitle><addtitle>J. Med. Chem</addtitle><date>1995-08-01</date><risdate>1995</risdate><volume>38</volume><issue>17</issue><spage>3391</spage><epage>3397</epage><pages>3391-3397</pages><issn>0022-2623</issn><eissn>1520-4804</eissn><abstract>We have designed 2'-C-cyano-2'-deoxy-1-beta-D-arabino- pentofuranosylcytosine (CNDAC) as a potential mechanism-based DNA-strand-breaking nucleoside, which showed potent tumor cell growth inhibitory activity against various human tumor cell lines in vitro and in vivo. When measuring the pKa of the 2' alpha-proton of CNDAC, we found that CNDAC epimerized to 2'-C-cyano-2'-deoxy-1-beta-D-ribo-pentofuranosylcytosine (CNDC) with concomitant degradation of both CNDAC and CNDC to cytosine and 1,4-anhydro-2-C-cyano-2-deoxy-D-erythro-pent-1- enitol. Kinetic analysis of these reactions showed that abstraction of the acidic 2'-proton of CNDAC and CNDC initiated the reactions, which quickly reached an equilibrium. In the equilibrium, a concentration ratio of CNDAC and CNDC was about 3:5. Concomitant degradation of these nucleosides was found to be rather slow. Deuterium incorporation experiments with CNDAC in a D2O buffer suggested the mechanism of the beta-elimination reactions is an E1cB type. These epimerization and degradation reactions were found even in neutral conditions (pH 7.5) and also occurred in RPMI 1640 cell culture medium. The discovery of which nucleoside possesses the predominate tumor cell growth inhibitory activity was important. While both nucleosides showed potent tumor cell growth inhibitory activity against three human tumor cell lines (colon carcinoma WiDr, small cell lung carcinoma SBC-5, and stomach carcinoma MKN-74 cells) in 48 h of incubation, in 20 min of incubation, CNDAC was 11-50 times more effective than CNDC. In vivo antileukemic activity of these nucleosides against a mouse P388 model, CNDAC was obviously superior to CNDC.</abstract><cop>United States</cop><pub>American Chemical Society</pub><pmid>7650692</pmid><doi>10.1021/jm00017a023</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0022-2623
ispartof Journal of medicinal chemistry, 1995-08, Vol.38 (17), p.3391-3397
issn 0022-2623
1520-4804
language eng
recordid cdi_proquest_miscellaneous_77463046
source MEDLINE; ACS Publications
subjects Adenocarcinoma - pathology
Animals
Antineoplastic Agents - chemical synthesis
Antineoplastic Agents - pharmacology
Cell Division - drug effects
Colonic Neoplasms - pathology
Cytarabine - analogs & derivatives
Cytarabine - chemical synthesis
Cytarabine - chemistry
Cytarabine - pharmacology
Drug Stability
Female
Humans
Hydrogen-Ion Concentration
Leukemia P388 - pathology
Mice
Mice, Inbred DBA
Ribonucleosides - chemical synthesis
Ribonucleosides - chemistry
Ribonucleosides - pharmacology
Spectrum Analysis
Tumor Cells, Cultured
title Nucleosides and Nucleotides. 141. Chemical Stability of a New Antitumor Nucleoside, 2'-C-Cyano-2'-deoxy-1-.beta.-D-arabino-pentofuranosylcytosine (CNDAC) in Alkaline Medium: Formation of 2'-C-Cyano-2'-deoxy-1-.beta.-D-ribo-pentofuranosylcytosine (CNDC) and Its Antitumor Activity
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T01%3A21%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Nucleosides%20and%20Nucleotides.%20141.%20Chemical%20Stability%20of%20a%20New%20Antitumor%20Nucleoside,%202'-C-Cyano-2'-deoxy-1-.beta.-D-arabino-pentofuranosylcytosine%20(CNDAC)%20in%20Alkaline%20Medium:%20Formation%20of%202'-C-Cyano-2'-deoxy-1-.beta.-D-ribo-pentofuranosylcytosine%20(CNDC)%20and%20Its%20Antitumor%20Activity&rft.jtitle=Journal%20of%20medicinal%20chemistry&rft.au=Azuma,%20Atsushi&rft.date=1995-08-01&rft.volume=38&rft.issue=17&rft.spage=3391&rft.epage=3397&rft.pages=3391-3397&rft.issn=0022-2623&rft.eissn=1520-4804&rft_id=info:doi/10.1021/jm00017a023&rft_dat=%3Cproquest_cross%3E16961104%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=16961104&rft_id=info:pmid/7650692&rfr_iscdi=true